196 related articles for article (PubMed ID: 16484702)
1. Relationship between cisplatin administration and the development of ototoxicity.
Rademaker-Lakhai JM; Crul M; Zuur L; Baas P; Beijnen JH; Simis YJ; van Zandwijk N; Schellens JH
J Clin Oncol; 2006 Feb; 24(6):918-24. PubMed ID: 16484702
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of gemcitabine and cisplatin in advanced non-small cell lung cancer: a preliminary report.
Shepherd FA; Burkes R; Cormier Y; Crump M; Feld R; Strack T
Lung Cancer; 1996 Feb; 14(1):135-44. PubMed ID: 8696717
[TBL] [Abstract][Full Text] [Related]
3. Ototoxicity due to cis-diamminedichloroplatinum in the treatment of ovarian cancer: influence of dosage and schedule of administration.
Waters GS; Ahmad M; Katsarkas A; Stanimir G; McKay J
Ear Hear; 1991 Apr; 12(2):91-102. PubMed ID: 2065844
[TBL] [Abstract][Full Text] [Related]
4. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ
Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Crul M; Schoemaker NE; Pluim D; Maliepaard M; Underberg RW; Schot M; Sparidans RW; Baas P; Beijnen JH; Van Zandwijk N; Schellens JH
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3526-33. PubMed ID: 14506138
[TBL] [Abstract][Full Text] [Related]
6. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
Shepherd FA; Cormier Y; Burkes R; Evans WK; Goss G; Klimo P; Feld R; Taylor M
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-27-S8-30. PubMed ID: 9207313
[TBL] [Abstract][Full Text] [Related]
8. Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Rademaker-Lakhai JM; Crul M; Pluim D; Sparidans RW; Baas P; Beijnen JH; van Zandwijk N; Schellens JH
Anticancer Drugs; 2005 Oct; 16(9):1029-36. PubMed ID: 16162981
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I/II study.
Steward WP; Dunlop DJ; Cameron C; Talbot DC; Kleisbauer JP; Thomas P; Guerin JC; Perol M; Sanson C; Dabouis G
Anticancer Drugs; 1995 Dec; 6 Suppl 6():33-7. PubMed ID: 8718423
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer.
Castellano D; Lianes P; Paz-Ares L; Hidalgo M; Guerra JA; Gómez-Martín C; Gómez H; Calzas J; Cortés-Funes H
Ann Oncol; 1998 Apr; 9(4):457-9. PubMed ID: 9636840
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and cisplatin treatment of advanced-stage non-small-cell lung cancer in patients given cisplatin on day 8.
Akcali Z; Calikusu Z; Sakalli H; Ozyilkan O
Tumori; 2008; 94(4):474-80. PubMed ID: 18822681
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose.
Shepherd FA; Burkes R; Cormier Y; Crump M; Feld R; Strack T; Schulz M
J Clin Oncol; 1996 May; 14(5):1656-62. PubMed ID: 8622085
[TBL] [Abstract][Full Text] [Related]
13. A new cisplatin/gemcitabine schedule in locally advanced (IIIB) and metastatic (IV) non-small cell lung cancer: relationship between dose-intensity and efficacy. A phase II study.
Rossi D; Graziano F; Catalano V; Giordani P; Fedeli SL; Alessandroni P; Fedeli A; Dennetta D; Ugolini M; Catalano G
Anticancer Res; 2002; 22(5):3087-92. PubMed ID: 12530048
[TBL] [Abstract][Full Text] [Related]
14. A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
Manegold C; Drings P; von Pawel J; Ricci S; Dornoff W; van Walree N; ten Bokkel Huinink W; Chemaissani A; Stahel P; Bergman B; Wagenius G; Sederholm C; Mattson K; Liippo K; Kellokumpu-Lehtinen P
Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-13-S8-17. PubMed ID: 9207310
[TBL] [Abstract][Full Text] [Related]
15. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
16. Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.
Soto Parra H; Cavina R; Latteri F; Sala A; Dambrosio M; Antonelli G; Morenghi E; Alloisio M; Ravasi G; Santoro A
Ann Oncol; 2002 Jul; 13(7):1080-6. PubMed ID: 12176787
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a cisplatin dose-ototoxicity model.
Dille MF; Wilmington D; McMillan GP; Helt W; Fausti SA; Konrad-Martin D
J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258
[TBL] [Abstract][Full Text] [Related]
18. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing.
Kopelman J; Budnick AS; Sessions RB; Kramer MB; Wong GY
Laryngoscope; 1988 Aug; 98(8 Pt 1):858-64. PubMed ID: 3398663
[TBL] [Abstract][Full Text] [Related]
19. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
Frisina RD; Wheeler HE; Fossa SD; Kerns SL; Fung C; Sesso HD; Monahan PO; Feldman DR; Hamilton R; Vaughn DJ; Beard CJ; Budnick A; Johnson EM; Ardeshir-Rouhani-Fard S; Einhorn LH; Lipshultz SE; Dolan ME; Travis LB
J Clin Oncol; 2016 Aug; 34(23):2712-20. PubMed ID: 27354478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
